Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Health

Now Available: EpiCast Report: Acute Coronary Syndrome (ACS) - Epidemiology Forecast to 2022


Print article Print article
2014-01-26 16:43:16 - New Pharmaceuticals market report from GlobalData: "EpiCast Report: Acute Coronary Syndrome (ACS) - Epidemiology Forecast to 2022"

Acute coronary syndrome (ACS) is a serious cardiovascular disease associated with high healthcare costs, frequent recurrences and hospitalizations, and high risks of sudden death and short-term mortality. The ACS incidence increases with age and will be a significant public health problem as the elderly population increases around the world. ACS is classified into three disease entities based on evidence of heart muscle damage inferred from a person's symptoms, changes in the ST-tracing of the electrocardiogram (ECG), and levels of cardiac biomarkers that signify heart muscle death: ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI), and unstable angina (UA). These three disease entities differ in their clinical characteristics, treatment approaches, and survival probabilities.

Full Report Details at
- www.fastmr.com/prod/764033_epicast_report_acute_coronary_syndrom ..

The epidemiology of

ACS in the 7MM has changed significantly during the past two decades and varies between the western and Japanese markets. In order to capture the country-specific trends and provide detailed patient population segmentation, GlobalData epidemiologists built separate forecasts for (myocardial infarction) (MI) and UA in the 7MM and used a case-flow methodology to determine the number of cases that survived until hospital discharge and for one year after hospital discharge.

GlobalData epidemiologists forecast that in the 7MM, the hospitalized incident cases of ACS will increase from 1.29 million cases in 2012 to 1.43 million cases in 2022 at the rate of 1.04% per year. The US constitutes around 40% of the total hospitalized incident ACS cases in the 7MM and will be the market with the highest number of cases during the forecast period. The majority of the cases occurred in men (58.15%) and in those ages =65 years (69.01%). For the 7MM, about 33% of the ACS cases were STEMI, 44% were NSTEMI, and 23% were UA. The proportions varied depending on the market.

Scope

The ACS EpiCast Report provides an overview of the ACS risk factors and comorbidities, a discussion of the ACS global and historical trends, and a 10-year epidemiological patient forecast for ACS from 2012 to 2022 in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). The epidemiological patient forecast includes -

* Hospitalized incident cases of ACS, segmented by STEMI, NSTEMI, and UA
* ACS cases that survived until hospital discharge, segmented by STEMI, NSTEMI, and UA
* ACS cases that survived for one year post-hospital discharge, segmented by STEMI, NSTEMI, and UA
* Diagnosed prevalent cases of myocardial infarction (MI) segmented by STEMI and NSTEMI from 2012 to 2022 in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK)
* The ACS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
* The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to Get this Report

* Develop business strategies by understanding the trends shaping and driving the global ACS market.
* Quantify patient populations in the global ACS market to improve product design, pricing, and launch plans.
* Organize sales and marketing efforts by identifying the patient segmentations that present the best opportunities for ACS therapeutics in each of the markets covered.
* Identify the number of ACS cases survived to key time periods.

Partial Table of Contents:

1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Upcoming Reports
3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.2.1 Controlling hypertension can decrease the CHD incidence by 20-25%
3.2.2 Every 1% decrease in cholesterol levels is associated with a 2% decrease in the CHD risk
3.2.3 Women who have diabetes have a higher risk of developing CHD than men with diabetes
3.2.4 Cigarette smoking increases the risk of CHD and also increases the risk of developing other risk factors for CHD
3.2.5 Obese and physically inactive persons are more likely to develop CHD through an increased risk of developing the traditional risk factors
3.2.6 Non-modifiable risk factors, such as family history, age, and sex, contribute to CHD development
3.2.7 Comorbidities
3.3 Global Trends - MI
3.3.1 MI Incidence and Mortality Trends
3.3.2 STEMI and NSTEMI Trends
3.3.3 Trends in MI Mortality and Case-Fatality Rates
3.3.4 MI Prevalence
3.4 Global Trends - UA
3.5 Forecast Methodology
3.5.1 Forecast Case Flow Map
3.5.2 Sources Used
3.5.3 Sources Not Used
3.5.4 Forecast Assumptions and Methods, Hospitalized MI Incident Cases
3.5.5 Forecast Assumptions and Methods, STEMI and NSTEMI Cases that Survived Until Hospital Discharge
3.5.6 Forecast Assumptions and Methods, STEMI and NSTEMI Cases That Survived for One Year After Discharge
3.5.7 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of MI
3.5.8 Forecast Assumptions and Methods, Hospitalized Cases of UA
3.5.9 Forecast Assumptions and Methods, UA Cases That Survived Until Hospital Discharge and for One Year Post-Discharge
3.6 Epidemiological Forecast for ACS (2012-2022) - Hospitalized Incident Cases
3.6.1 Hospitalized Incident Cases of ACS
3.6.2 Age-Specific Hospitalized Incident Cases of ACS
3.6.3 Sex-Specific Hospitalized Incident Cases of ACS
3.6.4 Hospitalized Incident Cases of ACS by STEMI, NSTEMI, and UA
3.6.5 ACS Cases That Survived Until Hospital Discharge and for One Year
3.6.6 Age-Specific ACS Cases That Survived Until Hospital Discharge
3.6.7 Age-Standardized Incidence of ACS
3.7 Epidemiological Forecast for MI (2012-2022) - Prevalent Cases
3.7.1 Diagnosed Prevalent Cases of MI

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=764033&dt=t

About GlobalData

GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at www.fastmr.com/catalog/publishers.aspx?pubid=1015

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.


Author:
Bill Thompson
e-mail
Web: www.fastmr.com
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com